GENEVA, Switzerland (AFP) — The World Health Organization (WHO) announced Wednesday that it had for the first time approved a “biosimilar” medicine — one derived from living sources rather than chemicals — to make breast cancer treatment affordable to women globally.
The Trastuzumab drug has shown “high efficacy” in curing early stage breast cancer and in some cases more advanced forms of the disease, the WHO said in a statement.
But the annual cost of the original drug is an average of $20,000, “a price that puts it out of reach of many women and healthcare systems in most countries,” the statement added.
However the biosimilar version of trastuzumab is generally 65 percent cheaper than the original.
“With this WHO listing, and more products expected in the prequalification pipeline, prices should decrease even further,” the WHO said.
The cheaper but equally effective biotherapeutic medicines are produced from biological sources such as cells rather than synthesized chemicals.
Three decades after the Marcopper mining disaster devastated Marinduque’s waterways, the province is again pressing the…
Housing is probably the biggest issue affecting people the world over.
Malacañang on Monday called for a more thorough investigation into the questioned flood control projects in Taguig…
The defense on Monday backed the move by senator-judges to exclude a prosecution witness who testified on the firearms…